Core Viewpoint - MoonLake Immunotherapeutics, a Swiss clinical-stage biotechnology company, is facing a class action lawsuit for allegedly misleading investors about the efficacy of its drug candidate SLK, which is aimed at treating inflammatory diseases driven by interleukin-17 (IL-17) [1][3]. Company Overview - MoonLake is focused on developing treatments for inflammatory diseases, particularly in dermatology and rheumatology, utilizing a unique Nanobody structure [1]. Legal Allegations - The lawsuit claims that during the class period, MoonLake failed to disclose critical information regarding the efficacy of SLK compared to BIMZELX, an FDA-approved drug. Key points include: - Both SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [3]. - The distinct Nanobody structure of SLK does not provide a clinical benefit over the traditional monoclonal antibody structure of BIMZELX [3]. - Claims of increased tissue penetration by SLK do not translate to improved clinical efficacy [3]. - The company lacked a reasonable basis for its positive statements regarding SLK's superiority [3]. Stock Performance Impact - Following the announcement of disappointing week-16 results from the Phase 3 VELA program on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4]. Class Action Participation - Shareholders may be eligible to participate in the class action against MoonLake. Those wishing to serve as lead plaintiffs must submit their papers by December 15, 2025 [5]. Legal Representation - Robbins LLP is leading the class action, specializing in shareholder rights litigation and has been active in helping shareholders recover losses and improve corporate governance since 2002 [6].

Accessibility StatementSkip Navigation Omvoh now offers patients a simplified maintenance experience with one monthly injection, replacing the previous two-injection regimen  Omvoh single-injection dosing will be available for U.S. patients in early 2026 This is the third FDA approval for Omvoh this year, following approvals for Crohn's disease and a citrate-free formulation INDIANAPOLIS, Oct. 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administrat ...

I going to make a greatest artwork as I can, by my head, my hand and by my mind./iStock via Getty Images Dear Fellow Shareholders, The Third Avenue Small-Cap Value Fund (the “Fund”) returned 7.18% during the third quarter of 2025, compared to a return of 8.97% for the MSCI USA Small Cap Value Index (the “Index”)1 and a return of 12.60% for the Russell 2000 Value Index.2 For the trailing three-year and five-year periods, the Fund produced annualized returns of 15.11% and 16.09%, respectively. Performance ...

Accessibility StatementSkip Navigation INDIANAPOLIS, Oct. 27, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on December 10, 2025, to shareholders of record at the close of business on November 14, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-ch ...

Core Viewpoint - ANI Pharmaceuticals (ANIP) is expected to exceed expectations in its third-quarter 2025 results, with revenue estimates at $211.3 million and earnings at $1.74 per share [1] Factors Shaping ANIP's Q3 Results - The company's revenue primarily comes from rare disease and generic pharmaceutical products, with significant growth driven by the uptake of rare disease products, particularly Cortrophin Gel [2] - Cortrophin Gel sales have increased due to rising demand, with expected revenues of $93 million for the third quarter [3] - ANIP's rare disease portfolio has expanded with the addition of Iluvien and Yutiq, contributing to revenue growth [5] Stock Performance - Year-to-date, ANI Pharmaceuticals shares have increased by 70.5%, significantly outperforming the industry average of 9.3% [4] Revenue Guidance - ANIP raised its full-year 2025 revenue guidance to $818-$843 million, reflecting a year-over-year growth of 33% to 37% [9] - Rare Disease products are projected to account for nearly 57% of total revenues in the second half of 2025 [9] Operating Expenses - Increased research and development expenses, along with higher selling and administrative costs, are likely to have raised operating expenses in the third quarter [10] Earnings Surprise History - ANI Pharmaceuticals has a strong history of earnings surprises, having beaten earnings estimates in the last four quarters with an average surprise of 22.66% [11] Earnings Prediction - The company's Earnings ESP is +6.24%, with the most accurate estimate at $1.85 per share, indicating a potential earnings beat [13]

A Coors beer sign in a Chicago bar. Molson Coors is one of four stocks singled out here as looking good on an indicator devised by the late market analyst Geraldine Weiss. (Photo by Scott Olson/Getty Images)Getty ImagesWhen a stock sports a dividend yield above its own historical average, one of two things has happened. The company may have raised its dividend – usually a good sign. Or, the dividend yield may have gone up because the stock’s price went down. That suggests there’s been bad news, but it hints ...

Organon CEO Kevin Ali has stepped down from his leading position at the company, following its board’s discovery of sales malpractice. This follows a probe from the board’s audit committee, which found that Organon was conducting “improper” wholesaler sales practices. This involved encouraging US-based wholesalers to buy more of the company’s contraceptive implant, Nexplanon, than they needed. According to the probe, wrongdoing occurred between 2022 and 2025, with the board identifying misconduct at the ...

BridgeBio Pharma (NASDAQ:BBIO) shares rose after it announced positive results from its late-stage study of BBP-418 on patients with limb-girdle muscular dystrophy type 2I/R9. The study successfully met all its main and secondary goals, showing a safety profile that aligns with ...

PhanuwatNandee/iStock via Getty Images Dear Baron Health Care Fund Shareholder: In the quarter ended September 30, 2025, Baron Health Care Fund® (the Fund) increased 5.39% (Institutional Shares), compared with the 5.05% gain for the Russell 3000 Health Care Index (the Benchmark) and the 8.18% gain for the Russell 3000 Index (the Index). Since inception (April 30, 2018), the Fund increased 9.30% on an annualized basis compared with the 8.68% gain for the Benchmark and the 14.48% gain for the Index. The F ...

Core Insights - Dr. Reddy's Laboratories Limited (RDY) reported Q2 fiscal 2026 earnings of 19 cents per American Depositary Share (ADS), exceeding the Zacks Consensus Estimate of 18 cents, and up from 17 cents per ADS in the same quarter last year [1][5] - Revenues increased by 9.8% year over year to $992 million, surpassing the Zacks Consensus Estimate of $983 million, primarily driven by growth in global generics revenues [1][5] Revenue Breakdown - Global Generics revenues reached INR 78.5 billion, reflecting a 10% year-over-year increase, mainly due to the acquired Nicotine Replacement Therapy portfolio in Europe and strong performance in branded markets [2] - Pharmaceutical Services & Active Ingredients (PSAI) revenues amounted to INR 9.5 billion, up 12% year over year, driven by new active pharmaceutical ingredients (APIs) and favorable foreign exchange [7] - Revenues in the Others segment totaled INR 0.1 billion, down 42% year over year [7] Regional Performance - North America segment revenues declined by 13%, attributed to increased price erosion in key products like Lenalidomide, although this was partially offset by favorable foreign exchange and contributions from new product launches [3] Product Development and Approvals - As of September 30, 2025, Dr. Reddy's had 75 generic filings pending FDA approval, including 73 abbreviated new drug applications (ANDAs) and two new drug applications, with 45 of the ANDAs being Para IVs [4] - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for AVT03, a proposed biosimilar to Amgen's Prolia and Xgeva, which is now under review by the European Commission [10][12] Financial Metrics - Gross margin decreased by 492 basis points to 54.7% due to higher price erosion in generics and reduced operating leverage [8] - Research and development (R&D) expenses were $70 million, down 15% year over year, as investments in biosimilars decreased following major funding completion for the Abatacept biosimilar candidate [8] - Selling, general and administrative expenses rose to $298 million, up 15% year over year, driven by increased sales and marketing investments [9] Strategic Moves - Dr. Reddy's announced an agreement to acquire the Stugeron portfolio from Johnson & Johnson, marking its entry into the anti-vertigo market, enhancing its central nervous system portfolio [16]